Close Menu

NEW YORK – In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health's Oncotype DX appear to benefit significantly from added chemotherapy.

Investigators led by the trial's PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the European Society for Medical Oncology 2019 Congress.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.